N/A
N=120
A Comparison of Two Daily Disposable Soft Contact Lenses
Visual Acuity
Bottom Line
View on ClinicalTrials.gov: NCT02427477 ↗Enrolled (actual)
120
Serious AEs
0.0%
Results posted
Jun 2016
Primary outcome: Primary: Subjective Overall Comfort — 75.5; 70.8 units on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- senofilcon A (Device); delefilcon A (Device)
- Age
- Adult · 18+ yrs
- Sex
- All
- Sponsor
- Johnson & Johnson Vision Care, Inc.
- Primary completion
- Apr 2015
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Subjective Overall Comfort |
75.5; 70.8 | — |
| PRIMARY Subjective Overall Vision |
75.3; 72.1 | — |
Summary
Approximately 120 subjects will be comparing two soft contact lenses for one week each.
Eligibility Criteria
Inclusion Criteria
- The subject must read, understand, and sign the Statement of Informed Consent, and receive a fully executed copy of the form.
- The subject must be appear able and willing to adhere to instruction set forth in this clinical protocol.
- The subject be between (and including) 18 and 39 years of age.
- The subject must be an adapted wearer of spherical soft contact lenses in both eyes. That is, the subject must wear their habitual lenses at least five (5) days per week and eight (8) hours per day worn for at least 30 days immediately preceding the study.
- The subject's vertex corrected spherical equivalent distance refraction must be in the range of -0.50 to -6.00 D in each eye.
- The subject must have best corrected visual acuity of 20/25 or better in each eye.
Exclusion Criteria
- Currently pregnant or breastfeeding (subjects who become pregnant during the study will be discontinued).
- Any ocular or systemic allergies or diseases that may interfere with contact lens wear.
- Any autoimmune disease or use of any medication, which may interfere with contact lens wear.
- Entropoin, Ectropion, extrusions, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions, or aphakia.
- Any previous, or planned ocular or intraocular surgery (e.g. radial keratotomy, PRK, LASIK, etc.)
- Any grade 3 or greater slit lamp findings (e.g. edema, corneal neovascularization, corneal staining, tarsal abnormalities, conjunctival injection) on the FDA classification scale, any previous history or signs of a contact lens-related inflammatory event (e.g. past peripheral ulcer or round scar), or any other ocular abnormality that may contraindicate contact lens wear.
- Any ocular infection.
- Any corneal distortion resulting from previous hard or rigid gas permeable contact lens wear.
- Monovision, multifocal, toric, or extended wear contact lens correction.
- Participation in any contact lens or lens care product clinical trial within 14 days prior to study enrollment.
- History of binocular vision abnormality or strabismus.
- Any infectious disease (e.g. hepatitis, tuberculosis) or contagious immunosuppressive disease (e.g. HIV) by self-report.
Data sourced from ClinicalTrials.gov (NCT02427477). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.